Raloxifene in breast cancer prevention

Expert Opinion on Drug Safety

Volumn 7, Issue 3, 2008, Pages 259-270

  Gennari, Luigi ^a   Merlotti, Daniela ^a   De Paola, Vincenzo ^a   Nuti, Ranuccio ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Breast cancer; Chemoprevention; Estrogen receptor; Raloxifene; SERMS

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; ARZOXIFENE; ESTRADIOL; ESTROGEN; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ANGINA PECTORIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE MODEL; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENDOMETRIAL DISEASE; ENDOMETRIUM CANCER; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HOT FLUSH; HUMAN; ISCHEMIA; LEG CRAMP; MONOTHERAPY; NONHUMAN; POSTMENOPAUSE; REVIEW; RISK REDUCTION; UTERUS CANCER; UTERUS DISEASE; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM; ANIMAL; BREAST TUMOR; FEMALE;

ANIMALS; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; POSTMENOPAUSE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 44949237995     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.3.259     Document Type: Review

References (98)

1. Jemal A, Siegel R, Ward F, et al. Cancer Statistics, 2007. CA Cancer J Clin 2007;57:43-66
2. Ferlay J, Bray F, Pisani P, et al. Globocan 2000: cancer incidence, mortality and prevalence worldwide, Version 1.0 Lyon: IARC Cancer Base No. 5. IARC Press; 2001
3. Ravdin PM, Cronin KA, Howlandr N, et al. The decrease in breast cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670-4
4. Clarke CA, Glaser SL, Uratsu CS, et al. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 2006;24:e49-50
5. Rossouw JE, Anderson JL, Prentice RL, et al. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-3
6. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896;2:104-7
7. Boyd S. On oophorectomy in cancer of the breast. BMJ 1900;2:1161-7
8. McGuire WL, Carbone PP, Volmer EP. Estrogen receptors in human breast cancer. New York: Raven Press; 1975
9. Meijer WJ, van Lindert AC. Prophylactic oophorectomy. Eur J Obstet Gynecol Reprod Biol 1992;47:59-65
10. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-85. Erratum in: N Engl J Med 2001;344:1804
11. Mukku VR, Stancel GM. Regulation of epidermal growth factor receptor by estrogen. J Biol Chem 1985;260:9820-4
12. Yee D, Lee AM. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia 2000;5:107-15
13. Vatten LJ, Kvinnsland S. Pregnancy-related factors and risk of breast cancer in a prospective study of 29981 Norwegian women. Eur J Cancer 1992;28A:1148-53
14. Riggs L, Hartmann LC. Selective estrogen-receptor modulators: mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-29
15. Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998;95:927-37
16. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997;389:753-8
17. Paige LA, Christensen DJ, Gron H, et al. Estrogen receptor (ER) modulators each induce distinct conformational changes in ERa and ERb. Proc Natl Acad Sci USA 1999;96:3999-4004
18. Jordan VC, Jaspan T. Tamoxifen as an antitumour agent: oestrogen binding as a predictive test for tumour response. J Endocrinol 1976;68:453-60
19. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-18
20. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:1993-2000
21. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-84
22. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67
23. Jordan VC. Effect of tamoxifen (ICI 46, 474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 1976;12:419-24
24. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88
25. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998;352:93-7
26. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101
27. Veronesi U, Maisonneuve P, Sacchini V, et al. Tamoxifen for breast cancer among hysterectomised women. Lancet 2002;359:1122-4
28. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360:817-24
29. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-62
30. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007;99:272-82
31. Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 2007;99:727-37
32. Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007;99:283-90
33. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300
34. Clemens JA, Bennett DR, Black LJ, Jones CD. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci 1983;32:2869-75
35. Escande A, Pillon A, Servant N, et al. Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta. Biochem Pharmacol 2006;71:1459-69
36. Grese TA, Sluka JP, Bryant HU, et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA 1997;94:14105-10
37. Sporne MB, Dowsett SA, Mershon J, Bryant HU. Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action. Clin Ther 2004;26:830-40
38. Thompson EW, Reich R, Shima TB, et al. Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res 1988;48:6764-8
39. Rajah TT, Pento JT. Influence of antiestrogens on the invasiveness and laminin attachment of breast cancer cells. Cancer Invest 1999;17:10-8
40. Fries G, Chalbos D, Vignon F. Anti-growth factor activities of benzothiophenes in breast cancer cells. Lilly Nonclinical Study Report. 2002 Apr. Contract No.:00251
41. Short LL, Glasebrook AL, Adrian MD, et al. Distinct effects of selective estrogen receptor modulators on estrogen dependent and estrogen independent human breast cancer cell proliferation. J Bone Miner Res 1996;1(1):5482
42. Buelke-Sam J, Bryant HU, Francio PC. The selective estrogen receptor modulator, raloxifene: an overview on nonclinical pharmacology and reproductive and developmental testing. Reprod Toxicol 1998;12:217-21
43. Bryant HU, Glasebrook AL, Yang NN, Sato M. A pharmacological review of raloxifene. J Bone Miner Metab 1995;14:1-9
44. Anzano MA, Peer CW, Smith JM, et al. Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 1996;88:123-5
45. Kubatka P, Bojkova B, Kaficka K, et al. Preventive effects of raloxifene and melatonin in N-methyl-N-nitrosourea-induced mammary carcinogenesis in female rats. Neoplasma 2001;48:313-9
46. Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 1987;47:4020-4
47. Wakeling AE, Valcaccia B. Antioestrogenic and antitumour activities of a series of non-steroidal antioestrogens. J Endocrinol 1983;99:455-64
48. Osborne CK, Hobbs K, Clark GM. Effect of estrogens and antiestrogens on growths of human breast cancer cells in athymic nude mice. Cancer Res 1985;45:584-90
49. Bryant HU. Selective estrogen receptor modulators. Rev Endocr Metab Dis 2002;3:231-41
50. Jordan VC, Morrow M. Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 1999;20:253-78
51. Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994;93:63-9
52. Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 1996;10:905-12
53. Fuchs-Young R, Magee DE, et al. Raloxifene is a tissue-specific anti-estrogen that blocks tamoxifen or estrogen stimulate uterotrophic effects. Endocrinology 1995;136:S57
54. Buzdar AU, Marcus C, Holmes F, et al. Phase II evaluation of LY156758 in metastatic breast cancer. Oncology 1988;45:344-5
55. Gradishar W, Glusman J, Lu Y, et al. Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer 2000;88:2047-53
56. Brodie AM, Njar VC. Aromatase inhibitors and breast cancer. Semin Oncol 1996;23:10-20
57. England GM, Jordan VC. Pure antiestrogens as a new therapy for breast cancer. Oncol Res 1997;9:397-402
58. di Salle E, Geroni C, Lamparelli M, et al. Chemopreventive effect of the aromatase inactivator exemestane combined with the antiestrogen raloxifene in the dimethylbenzanthracene (DMBA)-induced mammary tumors in rats. Am Soc Clin Oncol 2002;21:117a
59. Traina TA, Poggesi I, Robson M, et al. Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. Breast Cancer Res Treat 2007 [Epub ahead of print]
60. Masamura S, Santner SJ, Heitjan DF, et al. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995;80:2918-25
61. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9. Erratum in: Lancet 2002;360:1520
62. Dowsett M, Bundred NJ, Decensi A, et al. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev 2001;10:961-6
63. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7
64. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45. Erratum in: JAMA 1999;282:2124
65. Seeman E. Raloxifene. J Bone Miner Metab 2001;19:65-75
66. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281: 2189-97. Erratum in: JAMA 1999;281:2124
67. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65:125-34. Erratum in: Breast Cancer Res Treat 2001;67:191
68. Lippman ME, Krueger KA, Eckert S, et al. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. J Clin Oncol 2001;19:3111-6. Erratum in: J Clin Oncol 2001;20:1430
69. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-61
70. Lippman ME, Cummings SR, Disch DP, et al. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clin Cancer Res 2006;12:5242-7
71. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37
72. STAR: first-year recruitment efforts set brisk pace for future. CA Cancer J Clin 2000;50:271-2
73. Dunn BK, Ford LG. From adjuvant therapy to breast cancer prevention: BCPT and STAR. Breast J 2001;7:144-57
74. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41. Erratum in: JAMA 2006;296:2926 and JAMA 2007;298:973
75. Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999;91:1541-8
76. Cohen FJ, Lu Y. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas 2000;34:65-73
77. Martino S, Disch D, Dowsett SA, et al. Safety assessment of raloxifene over eight years in clinical trial setting. Curr Med Res Opin 2005;21:1441-52
78. Boss SM, Huster WJ, Neild JA, et al. Effects of raloxifrne hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997;177:1458-64
79. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13
80. Wassertheil-Smoller S, Hendrix S, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-84
81. Martino S, Costantino J, McNabb M, et al. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials. Oncologist 2004;9:116-25
82. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 2006;295:2742-51. Erratum in: JAMA 2007;298:973
83. Brown PH, Lippman SM. Chemoprevention of breast cancer. Breast Cancer Res Treat 2000;62:1-17
84. Uray IP, Brown PH. Prevention of breast cancer: current state of the science and future opportunities. Expert Opin Investig Drugs 2006;15:1583-600
85. Gradishar WJ, Cella D. Selective estrogen receptor modulators and prevention of invasive breast cancer. JAMA 2006;295:2784-6
86. Freedman AN, Graubard BI, Rao SR, et al. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003;95:526-32
87. Kelloff GJ, Lippman SM, Dannenberg AJ, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer: a plan to move forward. Clin Cancer Res 2006;12:3661-97
88. Cuzick J. Aromatase inhibitors in prevention: data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent results. Cancer Res 2003;163:96-103
89. Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial 18233230. J Bone Miner Res 2006;21:1215-23
90. Jonat W, Hilpert F, Kaufmann M. Aromatase inhibitors: a safety comparison. Expert Opin Drug Saf 2007;6:165-74
91. Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivals. J Clin Oncol 2007;25:3797-9
92. Jordan VC. SERMs: meeting the promise of multifunctional medicines. J Natl Cancer Inst 2007;99:350-6
93. NDA#022042. Available from: http://www.fda.gov/default.htm
94. Eng-Wong J, Reynolds JC, Venzon D, et al. Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. J Clin Endocrinol Metab 2006;91:3941-6
95. Jordan VC. Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial. Eur J Cancer 2006;42:2909-13
96. Gail MH, Castantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829-46
97. Feigelson HS, Henderson BE. Future possibilities in the prevention of breast cancer: role of genetic variation in breast cancer prevention. Breast Cancer Res 2000;2:277-82
98. Gennari L, Merlotti D, Valleggi F, et al. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging 2007;24:361-79